Amgen Inc. Files 10-Q for Q2 2024
Ticker: AMGN · Form: 10-Q · Filed: 2024-08-07T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report, biotech
Related Tickers: AMGN
TL;DR
Amgen's Q2 2024 10-Q is in. Check the numbers for the latest performance.
AI Summary
Amgen Inc. reported its second quarter 2024 results, ending June 30, 2024. The company's financial statements and business operations are detailed in this 10-Q filing. Key financial data and operational segments are presented for the periods ending June 30, 2024, and June 30, 2023.
Why It Matters
This filing provides investors and analysts with the latest financial performance and operational details for Amgen Inc., crucial for understanding the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine quarterly financial filing (10-Q) and does not inherently present new risks.
Key Numbers
- 2024 Q2 — Quarterly Period (Reporting period for the 10-Q filing.)
- 2024-06-30 — Period End Date (The end date for the reporting period.)
- 2023-06-30 — Prior Year Period End Date (For comparison with the current period.)
Key Players & Entities
- AMGEN INC (company) — Filer
- 20240630 (date) — Reporting Period End Date
- 20240807 (date) — Filing Date
- ONE AMGEN CENTER DRIVE (location) — Business Address
- THOUSAND OAKS (location) — City
- CA (location) — State
- 91320 (location) — ZIP Code
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on August 7, 2024.
What is Amgen Inc.'s primary business classification?
Amgen Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code [2836].
What is Amgen's corporate address?
Amgen's corporate address is One Amgen Center Drive, Thousand Oaks, CA 91320.
What specific financial instruments are mentioned in the filing's XBRL data?
The XBRL data mentions common stock (us-gaap:CommonStockMember) and 'A2.00 Senior Notes Due 2026' (amgn:A2.00SeniorNotesDue2026Member).
From the Filing
0000318154-24-000035.txt : 20240807 0000318154-24-000035.hdr.sgml : 20240807 20240806185426 ACCESSION NUMBER: 0000318154-24-000035 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 241180922 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 10-Q 1 amgn-20240630.htm 10-Q amgn-20240630 0000318154 false 2024 Q2 12/31 http://fasb.org/srt/2024#PartnershipInterestMember http://fasb.org/srt/2024#PartnershipInterestMember xbrli:shares iso4217:USD iso4217:USD xbrli:shares amgn:segment amgn:Segment xbrli:pure amgn:notice amgn:case iso4217:EUR iso4217:GBP amgn:patent amgn:securityCase 0000318154 2024-01-01 2024-06-30 0000318154 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0000318154 amgn:A2.00SeniorNotesDue2026Member 2024-01-01 2024-06-30 0000318154 2024-08-01 0000318154 us-gaap:ProductMember 2024-04-01 2024-06-30 0000318154 us-gaap:ProductMember 2023-04-01 2023-06-30 0000318154 us-gaap:ProductMember 2024-01-01 2024-06-30 0000318154 us-gaap:ProductMember 2023-01-01 2023-06-30 0000318154 us-gaap:ProductAndServiceOtherMember 2024-04-01 2024-06-30 0000318154 us-gaap:ProductAndServiceOtherMember 2023-04-01 2023-06-30 0000318154 us-gaap:ProductAndServiceOtherMember 2024-01-01 2024-06-30 0000318154 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-06-30 0000318154 2024-04-01 2024-06-30 0000318154 2023-04-01 2023-06-30 0000318154 2023-01-01 2023-06-30 0000318154 2024-06-30 0000318154 2023-12-31 0000318154 us-gaap:CommonStockMember 2023-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000318154 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000318154 2024-01-01 2024-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000318154 us-gaap:CommonStockMember 2024-03-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-03-31 0000318154 us-gaap:RetainedEarningsMember 2024-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000318154 2024-03-31 0000318154 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0000318154 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0000318154 us-gaap:CommonStockMember 2024-06-30 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2024-06-30 0000318154 us-gaap:RetainedEarningsMember 2024-06-30 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000318154 us-gaap:CommonStockMember 2022-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-12-31 0000318154 us-gaap:RetainedEarningsMember 2022-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000318154 2022-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000318154 2023-01-01 2023-03-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000318154 us-gaap:Common